Swiss pharma Orphan Technologies launches phase 1/2 clinical trial for OT-58 in classical homocystinuria
Orphan Technologies, a Swiss pharmaceutical company, has officially dosed the first patients in its groundbreaking phase 1/2 clinical trial, CBS-HCY-01, for OT-58, a modified recombinant ... Read More
Orphan Technologies starts OT-58 trial for homocystinuria treatment breakthrough
Swiss pharmaceutical company Orphan Technologies has begun dosing patients in a Phase 1/2 trial (CBS-HCY-01) to assess the safety and efficacy of its modified recombinant ... Read More